Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.

ABSTRACT:

Objectives

The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this modification could potentially retain efficacy benefits while improving on the manageable safety profile previously observed with this combination in patients with advanced renal cell carcinoma (aRCC).

Setting

Patients were enrolled from 48 largely community-based sites in the USA.

Participants

106 patients with previously untreated, predominantly clear cell aRCC received treatment.

Interventions

Patients received NIVO 6 mg/kg plus IPI 1 mg/kg on day 1 of the first week of each 8-week cycle; the combination alternated

SUBMITTER: George DJ 

PROVIDER: S-EPMC9476127 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature